Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?

Authors Ajoy Kumar, Vibhuti Singh

Published Date July 2010 Volume 2010:6 Pages 665—669

DOI http://dx.doi.org/10.2147/VHRM.S5686

Published 30 July 2010

Ajoy Kumar1, Vibhuti Singh2

1Bayfront Family Medicine Residency, St Petersburg FL, USA; 2University of South Florida College of Medicine and Suncoast Cardiovascular Center, St Petersburg, FL, USA

Abstract: When compared with the general population, the diabetic population is at higher risk of cardiovascular disease (CVD), as predicted by the Framingham Risk Score calculations (10-year risk 20%). For this reason diabetes is considered a “coronary disease equivalent” condition, as classified by the National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III. Furthermore, patients with diabetes who experience a myocar­dial infarction have a poorer prognosis than non­diabetic patients, which contributes to their overall higher mortality. Dyslipidemia is a major underlying risk factor contributing to the excess CVD risk, and is usually more atherogenic in the presence of diabetes. It is uniquely manifested by raised levels of triglycer­ides, low levels of high-density lipoprotein cholesterol, and smaller, denser, and more atherogenic low-density lipoprotein particles. Recent trials have suggested the need for more aggressive treatment of dyslipidemia in this subpopulation than the current recommendations by the NCEP-ATP III. This review addresses the newer developments in the diabetes arena in terms of our current understanding of atherogenic dyslipidemia in diabetes and data from the latest randomized trials addressing its management.

Keywords: atherogenic dyslipidemia, diabetes mellitus

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Matched case-control studies: a review of reported statistical methodology

Niven DJ, Berthiaume LR, Fick GH, Laupland KB

Clinical Epidemiology 2012, 4:99-110

Published Date: 27 April 2012

Validation of four automatic devices for self-measurement of blood pressure according to the international protocol of the European Society of Hypertension

Topouchian J, Agnoletti D, Blacher J, Youssef A, Ibanez I, Khabouth J, Khawaja S, Beaino L, Asmar R

Vascular Health and Risk Management 2011, 7:709-717

Published Date: 30 November 2011

Cardio classics revisited – focus on the role of candesartan

Maria Leonarda De Rosa

Vascular Health and Risk Management 2010, 6:1047-1063

Published Date: 23 November 2010

Management of acute attacks of hereditary angioedema: potential role of icatibant

Hilary J Longhurst

Vascular Health and Risk Management 2010, 6:795-802

Published Date: 6 September 2010

Management of high-risk popliteal vascular blunt trauma: clinical experience with 62 cases

Ali Pourzand, Bassir A Fakhri, Ramin Azhough, et al

Vascular Health and Risk Management 2010, 6:613-618

Published Date: 14 July 2010

Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome

Kanako Bokuda, Atsuhiro Ichihara, Mariyo Sakoda, et al

Vascular Health and Risk Management 2010, 6:571-578

Published Date: 5 July 2010

Influence of demographic and metabolic variables on forearm blood flow and vascular conductance in individuals without overt heart disease

Thiago E Sartori, Rafael AB Nunes, Gisela T da Silva, et al

Vascular Health and Risk Management 2010, 6:431-437

Published Date: 31 May 2010

Long-acting nifedipine in the management of the hypertensive patient

Morgan E Snider, Donald S Nuzum, Angie Veverka

Vascular Health and Risk Management 2008, 4:1249-1257

Published Date: 4 December 2008

Chronic heart failure in Japan: Implications of the CHART studies

Nobuyuki Shiba, Hiroaki Shimokawa

Vascular Health and Risk Management 2008, 4:103-113

Published Date: 6 March 2008

Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications

Brian C Cumbie, Kathie L Hermayer

Vascular Health and Risk Management 2007, 3:823-832

Published Date: 15 January 2007